News

News and Press Releases
Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX

Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.

| 2 min read
Our Research Approach Cystic Fibrosis Foundation Invests More Than $6.6 Million in Additional Funding in Sionna Therapeutics

The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.

| 2 min read
About the CF Foundation Bruce Marshall, Chief Medical Officer, to Retire From the CF Foundation

A transformative leader for more than two decades, Marshall will transition to advisory role

| 3 min read
Our Research Approach Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine’s prime editing technology has the potential to bring genetic therapies to all people with cystic fibrosis, ultimately paving the way to a cure.

| 4 min read
CF Foundation Establishes Health Equity Awards to Advance Research Toward Optimal Health Outcomes

The Foundation is committed to improving health outcomes for people with cystic fibrosis from underrepresented groups by supporting research projects advancing our understanding of barriers to health equity.

| 5 min read
In Memoriam CF Foundation Honors the Legacy of Joe O’Donnell

The Cystic Fibrosis Foundation mourns the passing of long-standing CF community champion and philanthropic leader who helped to raise more than $500 million toward the CF cause.

| 4 min read
Our Research Approach CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 

Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.

| 2 min read
Public Policy CF Foundation Grateful for Continued Access to Trikafta in Colorado After Prescription Drug Affordability Board’s Ruling

The Board’s review put Coloradans with CF at the center of the discussion, helping to preserve vital access to Trikafta®.

| 2 min read
Our Research Approach CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF

ViaNautis’ non-viral delivery mechanism, polyNaut®, aims to improve delivery of genetic therapies to the cells of people with CF. 

| 2 min read
About the CF Foundation | Diversity, Equity, and Inclusion CF Foundation Formalizes Final Set of Recommendations From External Racial Justice Working Group

The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.

| 4 min read